NCT00274924 · OUTCOME

5-year Overall Survival

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma · Source last updated 2023-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: probability
Interval / dispersion: 90% Confidence Interval
Time frame: Every 4 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then every 12 months if patient is 5-10 years from study entry.

What was measured

5-year overall survival is defined as the probability of patients who remain alive at 5 years from study entry. The method of Kaplan and Meier (1958) was used to estimate overall survival.

Groups in this outcome

Group I (PET Negative)

Eligible and treated patients who were PET negative after 3 cycles of R-CHOP received 2 more cycles of R-CHOP (6 cycles in total).

Group II (PET Positive)

Eligible and treated patients who were PET positive after 3 cycles of R-CHOP received 4 cycles of R-ICE.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Group I (PET Negative)	61
Group II (PET Positive)	13

Reported measurements

Source class 1

Values in probability · Interval/dispersion: 90% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Group I (PET Negative)	0.77	Not reported	0.49	0.91	Not reported
Group II (PET Positive)	0.69	Not reported	0.43	0.85	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
0.49
upper Limit
0.91
value
0.77
group Id
OG001
lower Limit
0.43
upper Limit
0.85
value
0.69

denoms

counts
group Id
OG000
value
61
group Id
OG001
value
13
units
Participants

description

5-year overall survival is defined as the probability of patients who remain alive at 5 years from study entry. The method of Kaplan and Meier (1958) was used to estimate overall survival.

dispersion Type

90% Confidence Interval

groups

description
Eligible and treated patients who were PET negative after 3 cycles of R-CHOP received 2 more cycles of R-CHOP (6 cycles in total).
id
OG000
title
Group I (PET Negative)
description
Eligible and treated patients who were PET positive after 3 cycles of R-CHOP received 4 cycles of R-ICE.
id
OG001
title
Group II (PET Positive)

param Type

NUMBER

reporting Status

POSTED

time Frame

Every 4 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then every 12 months if patient is 5-10 years from study entry.

title

5-year Overall Survival

type

SECONDARY

unit Of Measure

probability

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice